Good everyone. afternoon, Bob. you, Thank
how call plans positioned execute the and we've going Before we far how years goals. efforts quarter’s by come ourselves noting today, results, and the to on to I'm we some our the in few of dive last our framing start to into continue
seven by have Our been investments strategically guided objectives. planned and growth key
sizing global structure stages several in company's and to the order currently we the management. infrastructure, acquisitions, after service right are in footprint program final client First right of outmoded improve
as completing to as CRO model that with will our mid-sized a allow this feel and providers. well as competitively things research model objective provider. smaller diet As even more We larger us positioned and and well keep as CRO effectively research company full-service
third reduce Second, needs, party acquisitions. reliance for And client's in enhances provider. cost both doing through on the providers to a focus capabilities and our our for in able internal parties external on on we services. overall becoming third we turn, dependency full order so reduces speed, and This we customers. been reduce organically have to meet developed also quality, In service our value but
We support margin improvements. continued expect this will gross
updating global managing and have updated enterprise our Third, labs. and investments strategic our preclinical necessary which larger as capital resource appropriate that investments, customer her was laboratory and included Inotiv management enterprise solution well and now our systems, We've is our relationship planning as also significantly systems studies capital for technology organization.
maintenance leveraging and Inotiv. business expanding to growth deferred cost for acquired allow our to acquired we Additionally, and services as site rebranding, addressing Four, are committed our rebranded structure. and we've fixed facilities
bring and satisfaction, leadership, required. welfare, talented and standards and Six, monies animal recruiting passionate and included for complete spectrum driven providing should we more increased caring optimization welfare. to services. implementing more a facilities focusing that continued we to by has attention commitment our experienced expect site and training, from appropriate making when awareness retaining retain animal workplace investments plan our This staff, CRO, are and we regarding philosophy are And that provide clients environment recruiting and diligently passionate customers their are around the positive now of This further to top our Fifth, and goes have of a Workplaces lifesaving therapies way significant talent. the and shared this long we To we've purpose Award retaining around foster work compensation end, ability as year with entrepreneurial and combined a the to shared people of fair to to USA worked helping in our recipient world. seen very this earlier to improvement people. proud have and selected recruit retain Energage’s Top been purpose
us This reiterate became the been XXXX development In from for vendor assessment and we've XXXX people, supply from acquisitions, synergies, range biopharma volumes and of chain larger to mid-sized chain services to supply our vendor our a opportunities clients and companies objectives on additional and are underserved increased generate alternative story. synergies several prepared services. Seventh, working evolved has think to targeting and drug two being led reductions XXX XXXX, locations, broader supply chapter was That which today XXXX, with how firmly have also how organically. organization Inotiv these cost the company new purchasing with market. of to focus Early has focused important by our in safety began the segment the the our believe six completed acquisitions greater to next briefly key company from to and outlined on past of that we it's over small power realize. I preclinical enables we and CROs. that continue years, develop
years. four next the Over
toxicology, suppliers has toxicology. sand these clients’ improve genetic third margins grown needs, party and provided to service organically and our Pathology, value us range enhance reliance on our enabled reporting, our included now our reduce pharmacology, Expanding overall to Biotherapeutics of Clinical of the juvenile meet customers. Some safety offerings services to
discovery address XXXX, to a offerings our research providers. to ability to major to these needs, which Hiring supplier critical we risk our the and of a build businesses these our small in we In platform. research enhanced access major services, fiscal supply at in our provided began and these more we model large not our identified based and the provide acquisitions our ability strong subsequently research even XXXX, chain. both models acquisitions, DSA meet research became diets In year two through but to models complement access their preclinical customers expand foundation support with of only key to and additional Envigo and acquisition enhanced is also services Also, and the which to important. and secured the further models confidence other critical
enhancing improvements Ultimately, these strategic key to in remaining welfare. Now will infrastructure that while prioritized development, allow remain allowed consolidating to business access make of our facilities. our to which by new NHP is business, margins, in we team efforts believe and care regards we the increase improvements welfare veterinary competitive limited. Since into to continuing with facilities, model us us significant research the animal animal enlarging our expansion objective
Europe Today, over of through professionals service across X,XXX X,XXX now currently wide including employing over disciplines. offerings, these recognized operate customers acquisitions, and the range scientific eight sites US industry experts a organically and XX the worldwide, developed across serving we
the ability will a evolved with room we We those the be being serve require full get CRO we touch personal have future. in highly a who We month, better roof into a while But responsive products services under much of delivering to better and for have we still every breadth with clients credibility. believe and improvement. with services one and scientific
safety of diet If industry solutions standard you offering bedding to review services, assessment comprehensive development. and There and haven't support and page custom you'll encourage the a research website. extensive done so services, our I you models and research discovery, a find an recently, and clinical preclinical for
and At has spectrum present, by our programs advanced an organization enables with clinic that products. Inotiv gaps concept to services of strategic become the to clients from filling
take shifting story Inotiv’s profitability and our and we further And strategy to plan evolve Now to will as our next in continue growth. improve to service further shape continue XXXX in our our XXXX chapter. levels
revenues $XXX.X the to million, same mind, or Year-to-date results. last XXXX in the were period versus up With financial this year. let's get X%
to months same for and revenue and discovery model the X% as research services XX% Our period year and last respectively, compared nine safety assessment a for the ago. grew
The third the were $XXX.X with fiscal QX of XXXX XXXX performing vs X% of of revenues the year-over-year. XXXX. was year, QX down for Revenues quarter strongest quarter
first it was profitability. of our However, quarter
in driven increased services our by primarily the from services, with in -- genetic revenues Rockville X% in of from services in toxicology some decreased result biotech offset at decline which timing facility. funding discovery the market. our the toxicology revenue connection we by of the general the overall is believe DSA the business year-over-year somewhat a general QX, Plus new
This the sales for quarter volume reduce mainly was our revenue down offset somewhat important Integration and quarter. reduce cost. been increase due plans RMS to animal pricing. has to significantly target small this XX% NHP, for increased and remained on effectiveness by of
be finalized site UK, of into is announced eight We the and end ninth next of Blackthorn consolidation end nine previously the closures this and The have expected of by Hillcrest is to planned as year. is completed announced closure planned June. facility QX by previously
facility complete our small now addition, operations , Spain, In and a we Everett in to our to facility of in in complete expect expanding Washington which which closing in Colorado is Fort we Collins, QX fiscal we XXXX. relocate are will substantially
completed the now on this QX already XXXX. revenue of Over quarter begin of of the remains fiscal in XX of increase by we mainly to expansions Final work most now fill also planned this expect be the track book capacity, expansion fiscal have We the by fourth the to operations the completed operations. balance into year. completed. have largely facilities X of months, to last end are closed for XX consolidating closures these existing Moreover,
closed locations Boyertown quarters. focused regarding and completed are asset Cumberland, sites potentially the contract, in Haslett, along on next other these may over now be with believe are are in two and UK. sales the businesses, Michigan, sale We under our negotiations to assets from sale Spain, in which of ongoing France, including We three the Blackthorn which of were Israeli
Our restructure system integration our in the which opportunity transportation the to research site also is closures process. business, and models given for efforts currently us
margins operations. related consolidating our In to improve addition to
We of closure cash for also the will plant believe additional that company. for generate the sites sale
on XX% of online. to structure million bring XXXX. service XX% From us to recently we us expect XXXX our this future our sites, will in expansion leverage of capabilities by operations we DSA just focus $XXX projects of $XXX perspective DSA believe DSA infrastructure. investments the made to us XXXX allow with DSA our above cost an We and many which the will at from DSA allow grow footprint, in $XXX our from million XXXX sales million we've ultimately completed our realizing will Overall, to recently the facility estimated optimizing sales allow levels, benefits new fixed an to the in growth, to more to grow business also excess
affect reduce the expenses changes of restructuring these to NHP by imported lack are We to implemented. RMS to being capacity our also believe anticipate business after of into industry's proximately grow the all from the and We million have the supply we RMS models entire US. Cambodia expect imports research $XX continues
the Agricultural now to According XXXX. through of of Global NHPs at US same the lower USDA’s XXXX those imports XX.X% June to period Trade than year-to-date the System
We additional increase. to Pricing have and begun to our related and from identify of imports countries continue NHPs of outside NHPs of costs Cambodia. increased suppliers
to we've generate our continue margins; We positive requirements. meeting been customers’
assessment not by industry and impacted safety been have the service Our offerings shortage.
the suppliers than sufficient in in than not are we up We Cambodia QX countries QX. and in volume QX volume and less the than However, was NHP NHPs other QX, years. China NHP fewer Cambodia in for them to exports identified prior from make of did from sold available
we for to expect QX. fewer have than in in sale QX NHPs actually We available sold
if fiscal XXXX same, the XXXX stays sale in We fiscal fewer available versus XXXX. NHPs And NHP situation for in is expect will China the versus Cambodia fiscal XXXX. in fiscal less we and sell
trends, into all about average fairly our the implement to that XXXX to remained If quarters run have on ‘XX We to to increases And NHP pricing, exist Based of believe per XXXX. sales for this that will fiscal we achieve unknowns will our situation. for be volumes. similar we're continued consistent that million dollars $XX should despite taking lower rate could the through dollars in current the on in reduced see volumes. EBITDA able achievable able the normalized the price company future year, sales be increases, quarter. compared Due company account -- able be and
new sale, estimates increase. selling in As begin there and is an for of and increase to recently capacity available if we utilize the may DSA these added supply NHPs services,
we our or expect focus integrate We business RMS and to Cambodia. we key monitor in results and and our DSA initiatives, with from improvements situation NHP from segments continue see adjust and to without our our imports optimize continue as plans on will accordingly the
ability be to resolved maximize issue the the needs to this in lifesaving We understand in therapies industry's in a is US to US order significant important market. to and industry bring
discovery to term, our the portfolio between better how to medicines novel continued we the future, our and can continue correlations forward, a service and support embarked going program in development the that have explore the attracted team we our globally clinical data, and innovate of on customers, executing to of particularly optimize we their to that Longer and to find to Looking and we goal sector, standardize generated and have to assembled discovery, can service and skill accelerate offering. value data product in approach translational is structure we we medicine our integrate to confident in clinical vision. safety the our biopharma customer and of on proposition and outcomes in AI in have is experience are way safety data capture that them future, enable a studies. to our should The an as
With the financial Beth over I like the would turn for to to overview. this, call
